Rhythm Pharmaceuticals, Inc.
RYTM
$50.97
$0.731.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 68.06% | 81.55% | 132.57% | 173.52% | 227.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.06% | 81.55% | 132.57% | 173.52% | 227.56% |
| Cost of Revenue | 43.72% | 80.57% | 119.97% | 221.54% | 336.10% |
| Gross Profit | 71.38% | 81.67% | 134.26% | 168.25% | 216.79% |
| SG&A Expenses | 22.78% | 24.29% | 29.84% | 33.67% | 27.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.13% | 52.95% | 63.81% | 71.04% | 29.09% |
| Operating Income | -44.02% | -43.37% | -47.13% | -51.80% | -2.90% |
| Income Before Tax | -41.34% | -39.48% | -41.62% | -51.22% | -1.65% |
| Income Tax Expenses | -38.83% | 71.47% | -- | -- | -- |
| Earnings from Continuing Operations | -41.09% | -39.54% | -42.36% | -51.70% | -1.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.09% | -39.54% | -42.36% | -51.70% | -1.97% |
| EBIT | -44.02% | -43.37% | -47.13% | -51.80% | -2.90% |
| EBITDA | -44.55% | -43.90% | -47.68% | -52.36% | -2.88% |
| EPS Basic | -35.92% | -33.11% | -32.69% | -37.93% | 8.12% |
| Normalized Basic EPS | -34.13% | -31.73% | -32.17% | -38.32% | 7.86% |
| EPS Diluted | -35.92% | -33.11% | -32.69% | -37.93% | 8.16% |
| Normalized Diluted EPS | -34.13% | -31.73% | -32.17% | -38.32% | 7.86% |
| Average Basic Shares Outstanding | 5.77% | 6.07% | 7.67% | 8.98% | 10.67% |
| Average Diluted Shares Outstanding | 5.77% | 6.07% | 7.67% | 8.98% | 10.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
